No increase in serious asthma events occurs with fluticasone plus salmeterol, study showsBMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1349 (Published 07 March 2016) Cite this as: BMJ 2016;352:i1349
- Susan Mayor
Patients with asthma who were treated with a fixed dose combination of the long acting beta-agonist (LABA) salmeterol plus the inhaled glucocorticoid fluticasone had no higher risk of asthma related death or hospital admission than those on fluticasone alone,1 shows a randomised study that provides some reassurance after previous safety concerns.
But an accompanying editorial warned that the findings may not apply to patients with the most severe and unstable disease—the patients that guidelines say should be treated with LABAs plus inhaled glucocorticoid as first line therapy—because they were excluded from the study. …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial